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Indoleamine 2,3-dioxygenase (IDO) has been
described as a major mechanism of immunosup-
pression in tumors, though the mechanisms of this
are poorly understood. Here, we find that expression
of IDO by tumor cells results in aggressive tumor
growth and resistance to T-cell-targeting immuno-
therapies. We demonstrate that IDO orchestrates
local and systemic immunosuppressive effects
through recruitment and activation of myeloid-
derived suppressor cells (MDSCs), through amecha-
nism dependent on regulatory T cells (Tregs).
Supporting these findings, we find that IDO expres-
sion in human melanoma tumors is strongly associ-
ated with MDSC infiltration. Treatment with a selec-
tive IDO inhibitor in vivo reversed tumor-associated
immunosuppression by decreasing numbers of
tumor-infiltrating MDSCs and Tregs and abolishing
their suppressive function. These findings establish
an important link between IDO and multiple
immunosuppressive mechanisms active in the tumor
microenvironment, providing a strong rationale for
therapeutic targeting of IDO as one of the central reg-
ulators of immune suppression.INTRODUCTION
Indoleamine 2,3-dioxygenase (IDO) is expressed in many human
cancers, and high IDO expression is associated with advanced
disease stage and tumor metastasis in a variety of cancer types
(Munn, 2012). In cancer, IDO can either be expressed directly by
the tumor cells themselves or induced indirectly in host antigen-
presenting cells by the presence of tumor. By driving IDO over-
expression, tumors are able to create an immunosuppressive
microenvironment that blocks the antitumor immune response
(Prendergast et al., 2014). Several mechanisms of IDO-mediated412 Cell Reports 13, 412–424, October 13, 2015 ª2015 The Authorsimmune suppression have been described. IDO inhibits the acti-
vation of effector T cells (Teff) through depletion of the essential
amino acid tryptophan and promotes differentiation and activa-
tion of Foxp3+ regulatory T cells (Tregs) through production of
kynurenine (Munn and Mellor, 2007).
We have previously demonstrated in animal models that IDO
expression mediates resistance to cancer immunotherapy with
immunomodulatory antibodies targeting CTLA-4 and PD-1
(Holmgaard et al., 2013). Here, in order to delineate the mech-
anisms of tumor cell IDO-induced immunosuppression, we
developed a B16 melanoma model overexpressing IDO (B16-
IDO). When implanted into mice, B16-IDO tumors exhibited
aggressive tumor growth, characterized by rapid tumor pro-
gression and resistance to T cell-targeting immunotherapies.
This effect was associated with systemic expansion of myeloid
cells and marked recruitment of myeloid-derived suppressor
cells (MDSCs) into the tumor microenvironment. Importantly,
similar correlation between IDO expression and MDSC infiltra-
tion was seen in human melanoma samples and other animal
tumor models naturally expressing high levels of IDO. Inhibition
of IDO or depletion of Tregs resulted in reduction of MDSCs
and reversal of immune suppression. Our findings establish
tumor IDO expression as a key regulator of immunosuppres-
sion in the tumor microenvironment and on systemic level
and provide a strong rationale for therapeutic targeting of
this pathway.RESULTS
Suppressive MDSCs Are Highly Expressed in Melanoma
Patients with IDO-Positive Tumors
Munn et al. has previously shown that the presence of an abnor-
mally high level of IDO-expressing cells in the sentinel lymph
node (LN) of patients with malignant melanoma correlate with
poor long-term prognosis (Munn et al., 2004). Similarly, in our
studies, we find that the majority of patients (33 out of 36 cases)
with resected melanoma displayed high levels of IDO in their tu-
mors (Figure 1A). These findings suggested that IDOmight play a
mechanistic role in tumor progression and prompted us to
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Figure 1. IDO-Positive Tumors from Melanoma Patients Show Increased Frequencies of MDSCs
(A) Expression of IDO in tumor tissue from tumors of five patients with malignant melanoma determined by IHC.
(B) Representative IHC staining of CD14 and IDO in tissue from metastatic human melanoma tumors and the correlation between IDO and CD14 intensity.
(C) Intracellular staining and MFI for IDO within the CD45 gated population of cell suspensions obtained from metastatic melanoma tumors.
(D) Frequency of CD11b+CD33+CD14+HLA-DR/low cells in cell suspensions of IDO+ and IDO tumors and gating strategy.
(E) Expression of Arg1 in CD11b+CD33+CD14+HLA-DR/low gated population.
(F) T cell suppression assay with CD14+HLA-DR/low cells enriched from PBMCs or cell suspensions from tumors of patients with IDO+ tumors.
Data are representative of 36 patients (A), 33 patients (B), 22 patients (C–E), and 5 patients (F).examine the influence of IDO on the melanoma tumor microenvi-
ronment in more details.
Critical components of the tumor microenvironment include
immunosuppressive MDSCs. MDSCs in cancer patients have
been characterized by the expression of CD14, CD11b, CD33,
and Arg1 and low or absent expression of HLA-DR (Gabrilovich
et al., 2012). While analyzing the tumor microenvironment of
IDO-expressing tumors from patients with malignant melanoma,
we noted an increase in CD14+ cells. Using immunohistochem-
istry (IHC), we show that the intensity of CD14 expression is posi-
tively correlated with the intensity of IDO expression in these
tumors (Figure 1B). This was supported by analysis of data inCthe TCGA database showing a positive correlation between
IDO and CD14 mRNA in human melanoma (Figure S1). To
formally quantify this correlation, cell suspensions prepared
from tumor samples from patients with malignant melanoma
were stained for intracellular expression of IDO and divided
into IDO and IDO+ groups accordingly (Figure 1C). Supporting
our findings, by flow cytometry we found that the number of
CD11b+CD33+CD14+HLA-DR/low cells was significantly
increased in patients with IDO+ tumors (Figure 1D). When exam-
ining the functional capacity of the myeloid cells, we found that
the tumor-infiltrating CD11b+CD33+CD14+HLA-DR/low cells
were characterized by high expression of Arg1 (Figure 1E),ell Reports 13, 412–424, October 13, 2015 ª2015 The Authors 413
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Figure 2. Expression of IDO Promotes
Tumor Growth and Resistance to Immune
Checkpoint Blockade
(A) Mean weight and average growth rate of B16-
WT and B16-IDO tumors in naive and irradiated
mice.
(B) Levels of tryptophan and L-kynurenine in tumor
and blood evaluated by ELISA.
(C) Mean size of aCTLA-4 + aPD-1 treated B16-
IDO and B16-WT tumors and long-term survival.
Data are presented as mean ± SEM.indicating that these cells can be defined as MDSCs. Further-
more, we demonstrate that CD14+HLA-DR/low cells isolated
from IDO+ tumors were able to suppress proliferation of autolo-
gous CD8+ T cells in vitro (Figure 1F). In contrast, a similar pop-
ulation enriched from peripheral blood mononuclear cells
(PBMCs) was not suppressive (Figure 1F), suggesting that the
MDSCs are activated at the tumor site. These data suggested
that there may be a link between IDO expression and immuno-
suppressive MDSCs in cancer and prompted us to examine
the influence of IDO on tumor-infiltrating MDSCs in more detail
using experimental tumor models. For this purpose, we used
two different model systems: the murine B16 tumor cell line
transduced to overexpress IDO and the 4T1 tumor cell line
with known high endogenous IDO expression.
Expression of IDO in Melanoma Is Associated
with Aggressive Tumors
In contrast to the high levels of IDO expression observed in
human melanoma tissue (Figure 1A), we did not detect IDO414 Cell Reports 13, 412–424, October 13, 2015 ª2015 The Authorsexpression in the well-described murine
B16 melanoma cell line (Figure S2A).
This observation may reflect the hetero-
geneity of IDO expression in human tu-
mors. Thus, in order to model melanoma
cells expressing IDO, we generated a
B16 melanoma cell line overexpressing
IDO-GFP fusion protein (B16-IDO) and a
control cell line overexpressing GFP
alone (B16-WT). Expression of IDO was
confirmed by flow cytometry and western
blot analysis (Figures S2A and S2B).
When injected into naive mice, the B16-
IDO tumors grew significantly faster and
produced larger tumors (Figure 2A). IDO
expression did not influence the growth
of B16 cells in vitro (Figure S2C) or in irra-
diated naive mice (Figure 2A), suggesting
that the enhanced growth of the B16-IDO
tumors was not related to a higher
intrinsic growth rate of these cells. The
levels of tryptophan and its IDO-gener-
ated degraded product, L-kynurenine,
were evaluated by ELISA in blood and
tumor supernatants, demonstrating de-
creased level of tryptophan and increasedlevel of L-kynurenine in the B16-IDO tumors, but not in peripheral
blood (Figure 2B). To determine whether constitutive expression
of IDO by B16 cells carried any implications for efficacy of cancer
immunotherapy, animals bearing B16-IDO or B16-WT tumors
were treated with antibodies to CTLA-4, PD-1, or a combination
of both. While combination therapy led to 60% long-term animal
survival in the B16-WT tumor-bearing mice, B16-IDO tumors
were completely resistant to therapy (Figure 2C). Altogether,
these results suggest that IDO expression by B16 tumor cells
promotes tumor growth and resistance to immune checkpoint
blockade immunotherapy.
IDO Inhibits Proliferation and Accumulation
of Tumor-Specific T Cells at the Tumor Site
To assess tumor-specific immune responses in the B16-IDO and
B16-WT tumors, mice received a labeled cohort of activated
transgenic CD8+ T cells, recognizing a peptide from the melano-
somal antigen gp100 (pmel). In mice with B16-WT tumors, we
observed a robust proliferation and increase in number of pmels
in tumor-draining lymph nodes (TDLNs) as well as in tumors (Fig-
ure S2D). In contrast, pmels had significantly lower accumulation
in the B16-IDO tumors and TDLNs (Figure S2D). These data indi-
cate that tumor-expressed IDO leads to inhibition of proliferation
of tumor-specific T cells and prevents their accumulation at the
tumor site, whichmay be responsible for the observed enhanced
tumor progression.
Suppressive Myeloid Cells Are Expanded
in IDO-Expressing Tumors
To establish the mechanism responsible for the inhibition of tu-
mor-specific T cells in the IDO-expressing tumors, we analyzed
the tumor immune composition. While the absolute numbers of
CD45+ cells in the B16-IDO and B16-WT tumors were compara-
ble (Figure S3A), the relative frequency of CD3+ cells was signif-
icantly lower in the B16-IDO tumors (Figure 3A). This decrease in
CD3+ T cells corresponded to a diminished infiltration of both
CD8+ and CD4+ Teff cells (Figure 3B), but a notable increase in
Foxp3+ Tregs (Figure 3B). Activation of Tregs in tumor models
in vivo has previously been linked to IDO so this finding was
not surprising (Sharma et al., 2007). There were also decreased
percentages of CD19+ B cells, natural killer (NK) cells, and natu-
ral killer T cells (NKT) noted at the tumor site, but these differ-
ences did not reach statistical significance (Figures 3A and
3B). Importantly, there was a significant increase in myeloid
CD11b+ cells in the B16-IDO tumors compared to B16-WT tu-
mors (Figure 3A), resulting in decreased intratumoral ratio of
CD3+ T cells to CD11b+ cells (Figure 3C). Of note, the CD11b+
cells isolated from the B16-IDO tumors, but not from the B16-
WT, were capable of suppressing CD8+ T cell proliferation
in vitro (Figure 3D), suggesting that these cells may play a role
in the observed aggressiveness of the B16-IDO tumors.
Inhibition of IDO Blocks Expansion of Myeloid CD11b+
Cells in Tumors
To determine whether the expansion of CD11b+ cells in B16-IDO
tumors was indeed caused by IDO, mice with B16-IDO tumors
were treated with the IDO inhibitor indoximod (IDOi). Therapy
with IDOi reduced the growth rate and size of B16-IDO tumors
significantly (Figure 3E), which was associated with decrease
in the number of CD11b+ cells and increase in CD3+ T cells in tu-
mors (Figure 3F), resulting in increased CD3+/CD11b+ ratios
(Figure 3G). Furthermore, treatment with IDOi led to an increase
in CD4+ and CD8+ T cells in the tumor (Figure 3H) with upregu-
lation of the Teff cell marker CXCR3 on the tumor-infiltrating
CD8+ T cells (Figure 3I). To assess for tumor-specific responses,
we adoptively transferred activated pmels. IDOi treatment re-
sulted in an increase in and significant proliferation of pmels
within the TDLNs and tumors of B16-IDO tumor-bearing mice
(Figure 3J) and led to significantly reduced tumor growth (Fig-
ure S3B). These results indicate that tumor IDO expression not
only favors expansion of CD11b+ but also blocks trafficking
and proliferation of tumor-specific T cells at the tumor site.
CD11b+Cells Infiltrating IDO-Expressing Tumors Exhibit
MDSC Properties
In order to evaluate the distinct suppressive abilities of the
CD11b+ cells found in the B16-IDO and B16-WT tumors, weCinitially analyzed expression of the myeloid differentiation anti-
gen Gr1 (Ly6G). It has previously been demonstrated that the
intensity of Gr1 staining identifies CD11b+ cells with functional
heterogeneity (Gabrilovich and Nagaraj, 2009) that consist of
two major subsets with different Gr1 expression levels, termed
Gr1high and Gr1int cells, with Gr1high cells being nonsuppressive
(Dolcetti et al., 2010). The majority of the tumor-infiltrating
CD11b+ cells of both B16-IDO and B16-WT tumors expressed
Gr1 (Figure 4A). Interestingly, the increase in myeloid CD11b+
cells observed in the B16-IDO tumors corresponded to a pre-
dominant increase in the Gr1int population (Figure 4A). We found
that CD11b+Gr1int, but not CD11b+Gr1high, cells purified from
B16-IDO tumors were capable of suppressing T cell proliferation
(Figure 4B). Interestingly, CD11b+Gr1int cells isolated from B16-
WT tumors were incapable of suppressing CD8+ T cell prolifera-
tion (Figure 4B). The CD11b+Gr1int subsets from B16-IDO and
B16-WT tumors were then tested for differential expression of
various surface markers, which have previously been described
in tumor-derived CD11b+ cells with immunosuppressive proper-
ties (Dolcetti et al., 2010). Phenotypically, CD11b+Gr1int cells
from both B16-IDO and B16-WT tumors showed low levels of
major histocompatibility complex (MHC) class II and CD11c
and intermediate expression of F4/80 (Figure 4C), confirming
their status as immature myeloid cells and distinguishing them
from mature myeloid cells such as dendritic cells and macro-
phages. Furthermore, this population showed expression of
the typical monocyte marker Ly6C (Figure 4C). Thus, while we
were not able to distinguish the two CD11b+Gr1int populations
based on the majority of phenotypic markers, the cells demon-
strated clear functional differences with regards to immunosup-
pression. To this end, we observed that expression of inter-
leukin-4Ra (IL-4Ra) which has been suggested as a functional
marker of immunoregulatory CD11b+ cells (Gallina et al., 2006),
was higher in the CD11b+Gr1int population from B16-IDO tumors
(Figure 4D), and thus, IL-4Ra was the only predictive marker of
the suppressive activity. Taken together, these data indicate
that tumor IDO expression results in expansion of CD11b+Gr1int
cells, which possess immunosuppressive properties, consistent
with their functional definition as MDSCs. These results support
our initial findings in the patient tumor samples and thus highlight
an important link between IDO expression andMDSCs in cancer.
B16-IDO Tumor-Infiltrating MDSCs Upregulate
Arginase, iNOS, and Production of Immunosuppressive
Cytokines
To gain further insight into the different suppressive character of
CD11b+Gr1+ cells found in B16-IDO and B16-WT tumors, we
measured the production and expression of factors that have
been linked to the immunosuppressive activity of MDSCs (Gabri-
lovich et al., 2012). We observed that CD11b+Gr1int cells sorted
from B16-IDO tumors displayed significantly higher arginase-1
(Arg1) and nitric oxide (NO) production as compared to
CD11b+Gr1int cells from B16-WT tumors or to their granulocytic
CD11b+Gr1high counterparts (Figures 4E and 4F). In contrast,
CD11b+Gr1high subsets produced highly elevated levels of
ROS compared with CD11b+Gr1int cells, as evidenced by
increasedDCFDA incorporation (Figure S4A). To verify that these
molecules were indeed important for suppression, we measuredell Reports 13, 412–424, October 13, 2015 ª2015 The Authors 415
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Figure 3. IDO Promotes Expansion of Myeloid CD11b+ Cells in Tumors
(A) B16-IDO and B16-WT tumors were analyzed for infiltrating immune cells. Results for CD3+ T cells, CD19+ B cells, CD3NK1.1+ NK cells, and CD11b+myeloid
cells as frequencies of CD45+ cells and representative dot plots.
(B) Results for T cell subsets: NK1.1+ T cells (NKT), CD4+Foxp3+ Tregs, CD4+Foxp3 Teff cells, and CD8+ T cells as frequencies of CD45+ cells.
(C) CD3+/CD11b+ ratios.
(D) In vitro suppressive activity of CD11b+ cells from B16-IDO or B16-WT tumors. Representative histograms of CD8+ T cell proliferation are shown at a
CD11b+:CD8+ ratio of 1:1.
(E) Average growth and mean weight of IDOi- and vehicle-treated B16-IDO tumors.
(F) Relative percentages of CD11b+ and CD3+ cells of CD45+ cells in IDOi- and vehicle-treated B16-IDO tumors and representative flow plots.
(G) Calculated CD3+/CD11b+ ratios.
(H) Percent of tumor-infiltrating CD4+ and CD8+ T cells gated on the CD45+ population and representative plots.
(I) Example of CXCR3 staining within the CD8+ gated population.
(J) Representative plots and graphs showing percentage pmels of total CD8+ T cells in LN, TDLN, spleen, and tumor, and proliferation of pmels in tumor and
TDLNs, of IDOi- and vehicle-treated B16-IDO tumor-bearing mice.
Data are shown as mean ± SEM.T cell proliferation with CD11b+Gr1int cells obtained from B16-
IDO tumors in the presence of inhibitors of Arg1 and inducible
NO synthase (iNOS). Indeed, combination of Arg1 inhibitor with
iNOS inhibitor completely blocked the suppressive activity (Fig-
ure 4G). It has also been suggested that activated MDSCs pro-416 Cell Reports 13, 412–424, October 13, 2015 ª2015 The Authorsduce high levels of transforming growth factor-b (TGF-b) and
mediate their suppressive activity through PD-L1 expression
(Gabrilovich et al., 2012). To this end, the addition of either
aTGF-b or aPD-L1 antibody to Arg1 and iNOS inhibitors further
augmented T cell proliferation (Figure 4G). Using a transwell
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Figure 4. Phenotype and Suppressive Capabilities of Tumor-Infiltrating Myeloid CD11b+ Cells
(A) CD11b+ subsets obtained from B16-IDO and B16-WT tumors were evaluated for CD11b versus Gr1 expression and graphed as percent Gr1int and Gr1high
cells.
(B) Suppressive properties of CD11b+Gr1high and CD11b+Gr1int cells from B16-IDO or B16-WT tumors. Representative histograms of CD8+ T cell proliferation are
shown at a CD11b+:CD8+ T cell ratio of 1:1.
(C) CD11b+Gr1int subsets from B16-IDO and B16-WT tumors were evaluated for expression of F4/80, CD11c, MHC class II, and Ly6Cmarkers (open histograms)
against their matched isotype controls (filled histograms).
(D) IL-4Ra expression (open histograms) within the CD11b+Gr1int gated populations against matched isotype control (filled histograms).
(E) Arg1 activity in CD11b+Gr1high and CD11b+Gr1int subsets from B16-IDO and B16-WT tumors.
(F) Nitrite/NO concentration in supernatants of LPS-stimulated CD11b+Gr1high and CD11b+Gr1int cells.
(G) Suppressive activity of CD11b+Gr1int cells fromB16-IDO tumors in the presence of inhibitors of Arg1 (nor-NOHA), iNOS (L-NMMA), TGF-b (anti-TGF-b), and/or
PD-L1 (anti-PD-L1). Data are shown at a CD8+:CD11b+Gr1int ratio of 1:1.
(H) Suppressive activity CD11b+ cells fromB16-IDO tumors measured with CD11b+ cells in contact with CD8+ T cells or placed in 0.4-mmcell culture inserts. Data
are shown at a CD8+:CD11b+ ratio of 1:1.
Data are presented as mean ± SEM.system, we further found that inhibition of CD8+ T cell prolifera-
tion was contact dependent (Figure 4H). Importantly, increased
expression of Arg1, NO, TGF-b, PD-L1, and IL-4Ra was
confirmed on an mRNA level by real-time PCR (Figure S4B).
The upregulation of these molecules in CD11b+Gr1int cells from
B16-IDO tumors compared to CD11b+Gr1int cells from B16-
WT tumors could explain their distinct suppressive capacity.
Activation of MDSCs Is Dependent on Tumor-Expressed
IDO
We next proceeded to evaluate whether IDO was also required
for tumor-infiltrating CD11b+Gr1int cells to be activated and
become functional MDSCs. Treatment of B16-IDO tumor-
bearing animals with IDOi revealed a significant reduction in in-
tratumoral CD11b+Gr1int cells (Figure 5A), with a concomitant
decrease of IL-4Ra expression (Figure 5B) and loss of suppres-
sive activity in this subset (Figure 5C). Thus, inhibition of IDO not
only reduced the frequency of tumor-infiltrating MDSCs but also
inhibited their capability to suppress T cell proliferation, indi-
cating that activation of MDSCs in tumors requires IDO. Addition
of IDOi in vitro, on the other hand, did not restore T cell prolifer-Cation (Figure 5C), indicating that MDSCs do not exert their sup-
pressive capacity through expression of IDO. In support of the
latter, B16-IDO tumors grown in IDO/mice exhibited a similar
aggressive behavior and inhibition of IDO in these animals also
reduced tumor growth (Figure 5D) and increased ratios of intra-
tumoral CD3+ toCD11b+Gr1+ cells (Figure 5E), indicating that the
contribution of host-derived IDO is absent or minor in this model.
MDSCs Are Expanded in a Murine Model Expressing
Endogenous IDO
We next sought to determine whether IDO also drives the
expansion of MDSCs in a tumor model naturally expressing
high levels of IDO. Analysis of several murine cancer cell lines
revealed high levels of IDO expression in the 4T1 breast cancer
cell line when implanted in vivo (Figure S5). Interestingly, this
model has previously been shown to expand immunosuppres-
sive CD11b+Gr1int cells (Dolcetti et al., 2010). Treatment of 4T1
tumor-bearing mice with IDOi reduced the tumor growth rate
(Figure 5F). This was accompanied by a significant decrease
in the intratumoral CD11b+Gr1int cells, but not CD11b+Gr1high
cells (Figure 5G). Notably, CD11b+Gr1int cells purified fromell Reports 13, 412–424, October 13, 2015 ª2015 The Authors 417
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Figure 5. Activation of MDSCs Is Dependent on IDO Expression
(A) Frequencies of Gr1high and Gr1int subsets of total CD11b+ cells from B16-IDO tumors of IDOi- or vehicle-treated mice.
(B) MFI for IL-4Ra expression within the CD11b+Gr1int population.
(C) T cell suppression assay with CD11b+Gr1int cells purified from B16-IDO tumors in the presence of an IDOi added in vitro or administered in vivo.
(D) Growth curve for B16-IDO tumors in IDOi treated IDO/ mice.
(E) Ratio of CD3+ to CD11b+Gr1+ cells in B16-IDO tumors in IDOi-treated IDO/ mice.
(F) Average growth rate and mean weight of IDOi- and vehicle-treated 4T1 tumors.
(G) Relative percentages of Gr1+ of total CD11b+ cells in 4T1 tumors after IDOi therapy.
(H) IL-4Ra expression within the CD11b+Gr1int gated population of TILs from untreated 4T1 tumor-bearing mice.
Data are presented as mean ± SEM.the 4T1 tumors were characterized by expression of IL-4Ra
(Figure 5H), suggesting that this cell population is indeed
immunosuppressive.
Tumor IDO-Induced Expansion of MDSCs Is Systemic
Expansion of MDSCs has been previously described in the
spleens of EL-4, CT26, and 4T1 mouse tumor models (Dolcetti
et al., 2010; Youn et al., 2008), suggesting that tumors drive sys-
temic MDSC expansion. Similar to these findings, analysis of
spleens from B16-IDO tumor-bearing mice revealed expansion
of CD11b+ cells (Figure 6A), with predominance ofGr1+ cells (Fig-
ure 6B). Surprisingly, while the CD11b+Gr1int splenocytes from
the 4T1 and EL-4 tumor-bearing mice were shown to possess
immunosuppressive activity (Dolcetti et al., 2010; Youn et al.,
2008), the CD11b+Gr1int cells from spleens of B16-IDO tumor-
bearing mice did not suppress CD8+ T cell proliferation (Fig-
ure 6C). While these splenic CD11b+Gr1int cells were phenotypi-
cally similar to the corresponding CD11b+Gr1int cells isolated
from B16-IDO tumors (Figure S6A), they produced significantly
lower levels of Arg1 (Figure S6B) and NO (Figure S6C) and418 Cell Reports 13, 412–424, October 13, 2015 ª2015 The Authorsshowed lower expression of IL-4Ra (Figure S6D). The splenic
expansion of CD11b+Gr1int cells could be significantly reduced
whenmicewere treatedwith IDOi (Figure S6E), further confirming
the role of IDO in controlling this process.
Recruitment of CD11b+Gr1int Cells and Activation of
Immunosuppressive Properties Are Dependent on the
Tumor Microenvironment
The findings above suggested that while B16-IDO tumors induce
systemic expansion of the CD11b+Gr1int cells, the tumor micro-
environment might be necessary to render them suppressive. To
explore this possibility, we established bilateral flank tumor
models bearing B16-IDO tumors in one flank and B16-WT
tumors in the contralateral flank (Figure 6D). Remarkably, B16-
IDO tumors resulted in enhanced growth of B16-WT tumors on
the contralateral flank (Figure 6E), which was associated with
an increase in CD11b+Gr1int cells in the B16-WT tumors (Fig-
ure 6F) and acquisition of immunosuppressive properties by
these cells (Figure 6G). Consistent with their suppressive activity,
these cells were characterized by increased expression of
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Figure 6. Local and Systemic Effects of Tumor IDO Expression
(A) Frequencies of CD11b+ myeloid cells and CD3+ T cells of total CD45+ cells in splenocytes from B16-IDO and B16-WT tumor-bearing mice and representative
dot plots.
(B) Expression of Gr1 within the CD11b+ gated population and representative plots.
(C) Suppressive properties of CD11b+Gr1int splenocytes from B16-IDO tumor-bearing mice.
(D) Bilateral flank tumor models: (1) B16-WT tumors on both flanks, (2) B16-IDO tumors on both flanks, and (3) B16-IDO tumor on one flank and B16-WT on the
contralateral flank.
(E) Mean growth and weight of bilateral flank tumors.
(F) Infiltration of CD11b+Gr1int and CD11b+Gr1high myeloid cells in bilateral flank B16-IDO and B16-WT tumors.
(G) Suppressive activity of CD11b+Gr1int cells from B16-IDO or B16-WT tumors of bilateral flank tumor-bearing mice and representative histograms.
(H) MFI for IL-4Ra expression within CD11b+Gr1int and CD11b+Gr1high gated populations.
(I) Frequencies of CD11b+ and CD3+ of CD45+ total cells and CD3+:CD11b+ ratios in bilateral flank B16-IDO and B16-WT tumors, and representative plots.
(J) Frequencies of CD8+, CD4+Foxp3, and CD4+Foxp3+ cells of CD45+ total cells in bilateral flank B16-IDO and B16-WT tumors.
(K) Mean tumor growth of aCTLA-4 + aPD-1 and/or IDOi treated B16-IDO and B16-WT tumors in bilateral flank tumor models.
(L) Migration of CD11b+Gr1int splenocytes purified from B16-IDO and B16-WT tumor-bearing mice toward homogenized tumors, sorted tumor cells or tumor cell
lines as indicated.
(M) Suppressive activity of CD11b+Gr1int splenocytes of B16-IDO and B16-WT tumor-bearing mice pre-cultured with homogenized tumors, sorted tumor cells or
tumor cell lines. CD11b+Gr1int cells were pre-cultured in contact with tumor cells or placed in 0.4 mm cell culture inserts as specified.
(N) Relative levels of soluble factors in supernatants of B16-IDO tumors compared to B16-WT tumors, as determined by Luminex.
Data are presented as mean ± SEM.IL-4Ra (Figure 6H). In addition, we observed lower percentages
of CD3+ T cells in these tumors and, as a result, a decrease in the
intratumoral ratio of CD3+ T cells to CD11b+ cells (Figure 6I). The
observed decrease in CD3+ T cells was due to reduction of both
CD4+Foxp3 and CD8+ T cells, but not CD4+Foxp3+ Tregs (Fig-Cure 6J). Notably, the anti-tumor effect of aCTLA-4 + aPD-1 com-
bination therapy in the B16-WT tumor model was also
completely lost in the B16-IDO/B16-WT bilateral flank tumor
model, and this could be overcome by therapeutic inhibition of
IDO with IDOi (Figure 6K). Altogether, these results demonstrateell Reports 13, 412–424, October 13, 2015 ª2015 The Authors 419
that the IDO-driven expansion of CD11b+Gr1int cells is indeed
systemic but requires the effect of the tumor microenvironment
for activation of their suppressive activity.
To understand the mechanisms of expansion of CD11b+Gr1int
cells in tumors, we analyzed bromodeoxyuridine (BrdU) incorpo-
ration in CD11b+Gr1int cells in bone marrow (BM), blood, spleen,
and tumor tissue of B16-IDO tumor-bearing mice. High percent-
ages of BrdU+ CD11b+Gr1int cells were mainly detected in BM
and in spleens, but not in tumors (Figure S6F), suggesting that
their accumulation in tumors is likely due to the recruitment
from the periphery and less likely due to proliferation at the tumor
site. In support of this hypothesis, splenic CD11b+Gr1int cells ex-
hibited an increased ability to migrate through collagen-coated
culture inserts toward B16-IDO tumors in vitro, which was not
observed with B16-WT tumors (Figure 6L). This effect required
all components of the tumor microenvironment to be present,
as migration was significantly diminished toward tumor cells
sorted from B16-IDO tumors and completely lost when B16-
IDO tumor cell lines cultured in vitro were used as attractants
(Figure 6L).
These findings thus suggest that the CD11b+Gr1int cells likely
traffic into the tumor microenvironment from the periphery. To
determine whether CD11b+Gr1int cells are functionally activated
by the B16-IDO tumors, CD11b+Gr1int splenocytes purified from
B16-IDO or B16-WT tumor-bearing mice were cultured with
B16-IDO or B16-WT tumors and tested for the capacity to sup-
press CD8+ T cell proliferation. We found that CD11b+Gr1int cells
cultured in the presence of B16-IDO tumors, but not B16-WT tu-
mors, were able to suppressCD8+ T cell proliferation (Figure 6M).
The establishment of suppressive capabilities did not require
direct contact between CD11b+Gr1int MDSCs and tumors as
suppression was also observed when CD11b+Gr1int MDSCs
were separated from the tumors by a porous membrane (Fig-
ure 6M). CD11b+Gr1int cells co-cultured with B16-IDO tumor
cells sorted from tumors also acquired suppressive capability,
albeit lower, while co-culture with the in vitro-cultured B16-IDO
cell line had no effect (Figure 6M). These results indicate that
CD11b+Gr1int cells gain their suppressive capacity at the
tumor site and suggest that this is mediated by soluble factors,
likely produced by different components of the tumor
microenvironment.
The B16-IDO Tumor Microenvironment Contains High
Levels of Pro-inflammatory Cytokines and Chemokines
To identify the potential mediators of the preferential accumula-
tion and activation of CD11b+Gr1int MDSCs in the B16-IDO tu-
mors, the expression of chemokines, inflammatory cytokines,
and growth factors in tumors was analyzed, revealing increased
expression of multiple factors in the B16-IDO tumors (Figure 6N).
The most differentially expressed factors were TNF-a, IL-10,
IL-4, IL-6, IL-2, interferon-g (IFN-g) IL-13, MIG, MCP-1, MIP-
1a, and IP-10 and two growth factors, vascular endothelial
growth factor (VEGF) and granulocyte-macrophage colony-
stimulating factor (GM-CSF) (p values < 0.01) (Figure 6N).
Several of these factors have been described to be implicated
in the recruitment of MDSCs and monocytes as well as the
expansion, activation, and function of MDSCs and are known
to be produced by tumor cells, T cells, or activated MDSCs420 Cell Reports 13, 412–424, October 13, 2015 ª2015 The Authorsthemselves (Gabrilovich and Nagaraj, 2009). Interestingly,
despite being immunosuppressive, the B16-IDO tumor microen-
vironment appeared to exhibit markedly higher levels of pro-in-
flammatory cytokines, suggesting that the recruitment and/or
activation of MDSCs in the B16-IDO tumor could be a part of
an adaptive immune response.
Accumulation of MDSCs in Tumors Is Dependent
on Adaptive Immunity
These results prompted us to examine the accumulation and
functional capacity of CD11b+Gr1+ cells in B16-IDO tumors
grown in Rag/ mice, deficient in T and B cells (Mombaerts
et al., 1992). We observed that the absolute number of
CD11b+Gr1+ cells in tumors was significantly reduced when
B16-IDO tumors were implanted in Rag/ mice (Figure 7A),
while this reduction was not apparent in B16-WT tumors im-
planted in Rag/ mice (Figure 7A). Furthermore, CD11b+Gr1+
cells purified from B16-IDO tumors harvested from Rag/
mice were no longer able to suppress proliferation of CD8+
T cells (Figure 7B). Finally, the migration of splenic CD11b+Gr1+
cells toward B16-IDO tumors grown in Rag/ mice was
completely lost (Figure 7C). Together, these data show that the
adaptive immune response (i.e., T and/or B cells) is likely
required for recruitment and functional activation of MDSCs in
B16-IDO tumors.
In previous studies, IDO expression has been demonstrated to
induce and activate Foxp3+ Tregs (Munn and Mellor, 2007). As
the only adaptive population that increased in the B16-IDO tu-
mors was Foxp3+ Tregs (Figure 3B), we hypothesized that the
IDO-mediated activation of Tregs may be responsible for the
observed MDSC expansion. To examine the role of Tregs in
IDO-mediated MDSC recruitment, we first tested the frequency
and suppressive capacity of the Tregs in the B16-IDO tumors.
For this purpose, we used transgenic mice expressing Foxp3-
GFP fusion protein (Foxp3GFP knockin mice), which allowed us
to specifically detect and sort live Foxp3+ Tregs (Fontenot
et al., 2003). Similar to what we observed in wild-type mice (Fig-
ure 3B), the frequency and absolute number of Foxp3+ Tregs
was significantly higher in B16-IDO tumors than B16-WT tumors
when tumors were harvested from Foxp3GFP mice (Figure 7D).
Moreover, Tregs purified fromB16-IDO tumorswere significantly
more potent in suppressing CD8+ T cell proliferation than Tregs
from B16-WT tumors (Figure 7E). These data show that tumor
IDO expression changes both the quantity and the suppressive
function of tumor-infiltrating Tregs.
Systemic Depletion of Foxp3+ Tregs Inhibits
Recruitment and Functional Activation of MDSC
in IDO-Expressing Tumors
To evaluate the influence of Tregs on accumulation and activa-
tion of MDSCs in vivo, we utilized a transgenic mouse strain en-
gineered with a transgene that expresses the diphtheria toxin re-
ceptor (DTR) under control of the Foxp3 promoter (Foxp3DTR
mice). In Foxp3DTR mice, diphtheria toxin (DT) administration re-
sults in 90%–95% depletion of Foxp3+ Tregs within 3 days of
daily injection (Li et al., 2010). DT treatment resulted in near-com-
plete elimination of Foxp3+ Tregs in TDLNs, spleens, and tumors
in B16-IDO tumor-bearing Foxp3DTR mice (Figure S7).
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Figure 7. Accumulation of MDSCs in Tumors Is Dependent on the Adaptive Immune Response
(A) Absolute number of CD11b+Gr1+ cells per gram of tumor in B16-WT and B16-IDO tumors from wild-type (WT) and Rag/ mice.
(B) In vitro suppressive activity of CD11b+Gr1int cells purified from B16-IDO tumors of WT or Rag/mice measured in CD11b+Gr1int to CD8+ T cell ratios of 1:1.
(C) Migration of CD11b+Gr1int splenocytes of B16-IDO tumor-bearing mice toward B16-IDO tumors harvested from WT or Rag/ mice.
(D) Frequency of Foxp3+ Tregs of total CD3+ T cells in B16-IDO and B16-WT tumors of Foxp3GFPmice. Representative dot plots showingGFP-Foxp3+ expression
within CD45+ gated populations.
(E) Suppressive properties of Foxp3+ Tregs sorted from B16-IDO and B16-WT tumors of Foxp3GFP mice. Representative histograms of CD8+ T cell proliferation
are shown at a Foxp3+ Treg to CD8+ T cell ratio of 1:1.
(F) Frequency of CD11b+Gr1int cells of total CD45+ cells in tumor, TDLNs and spleens of B16-IDO tumor-bearing Foxp3DTR mice injected with DT or PBS.
(G) Suppression assay with CD11b+Gr1int cells purified from B16-IDO tumors of Foxp3DTR mice injected with DT and PBS. Representative histograms showing
CD8+ T cell proliferation at a CD8+:CD11b+Gr1int ratio of 1:1.
(H) Migration of CD11b+Gr1int splenocytes toward homogenized B16-IDO tumors from Foxp3DTR, WT or Rag/ mice. Tumors were pre-incubated with Treg-
blocking antibody or tumor-infiltrating Treg and/or Teff cells in vitro, as indicated.
(I) Frequency of CD8+CXCR3+ T cells of total CD3+ T cells B16-IDO tumors of Foxp3DTR mice injected with DT or PBS.
(J) Mean growth rate and weight of B16-IDO tumors in Foxp3DTR mice injected with DT or PBS.
(K) Percentage of CD4+Foxp3+ Tregs and CD69+CD8+ T cells in cell suspensions of IDO+ and IDO human metastatic melanoma tumors.
(L) Representative IHC staining of IDO, CD14, and Foxp3 in tissue from metastatic human melanoma tumors.
Data represent mean ± SEM (A–E) or one representative experiment (F–J). Data in (K) and (L) are representative of 22 patients.
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Remarkably, DT treatment led to a reduction in CD11b+Gr1int
MDSCs in the tumors and spleens (Figure 7F). Furthermore,
CD11b+Gr1int cells purified from B16-IDO tumors treated with
DT were significantly less suppressive in vitro than CD11b+Gr1int
cells from untreated B16-IDO tumors (Figure 7G). To investigate
the role of Tregs on the recruitment of MDSCs to the tumor site,
we performed migration experiments using B16-IDO tumors
grown in Foxp3DTR mice treated with DT. Consistent with the
findings described above, there was almost a complete loss of
migration of CD11b+Gr1int splenocytes toward Treg-depleted
B16-IDO tumors (Figure 7H). Similar, findings were observed
when B16-IDO tumors were pre-incubated with Treg-blocking
antibody in vitro prior to using them as attractants in the migra-
tion assay (Figure 7H). Importantly, migration was partially
restored by addition of supernatant from non-Treg depleted
B16-IDO tumors of Foxp3DTR mice (Figure 7H). Similarly, the
migration of CD11b+Gr1int splenocytes to B16-IDO tumors
harvested from Rag/ mice could be restored by addition of
B16-IDO tumor-infiltrating Tregs in vitro (Figure 7H), but not by
addition of tumor-infiltrating CD3+Foxp3 Teff (Figure 7H). The
migration was increased further by addition of both tumor-infil-
trating Tregs and Teff cells (Figure 7H). Altogether, these data
suggest that tumor-infiltrating Tregs and to some extent effector
T cells play a role in the recruitment and activation of suppressive
MDSCs. Finally, depletion of Foxp3+ Tregs resulted in signifi-
cantly greater accumulation of effector CD8+CXCR3+ T cells at
the tumor site (Figure 7I) and led to significant delay in tumor
growth (Figure 7J). Supporting these findings, we observed a
significant increase in Foxp3+ Tregs in the IDO+ human mela-
noma tumor samples along with decrease in CD8+CD69+
T cells (Figures 7K and 7L). In summary, our findings establish
a link between IDO, Tregs, and MDSCs, which may help to
explain the highly immunosuppressive nature of the IDO-ex-
pressing tumors. At present, the mechanisms of Treg-mediated
MDSC recruitment and activation are not fully understood and
further studies will be needed to investigate these pathways.
DISCUSSION
Tumors use a variety of suppressive strategies to escape from
antitumor immune responses. In particular, upregulation of IDO
in tumors has been associated with poor prognosis (Munn,
2012). IDO catabolizes the initial rate-limiting reaction of the
kynurenine pathway. Several mechanisms of IDO-mediated im-
mune suppression have been described. Both tryptophan deple-
tion and kynurenine accumulation exert immune regulatory ef-
fects leading to T cell suppression and Treg induction, among
other things (Munn and Mellor, 2007).
To better understand the mechanisms of tumor IDO-mediated
immune suppression, we developed a tumor model overex-
pressing IDO (B16-IDO), which allowed us to isolate the effects
of IDO expression by comparing it to the parental B16-WT cell
line. IDO-expressing B16 tumors exhibited aggressive tumor
growth and, in addition to lack of tumor-specific T cells at the tu-
mor site, unexpectedly were characterized by a high infiltration
of CD11b+Gr1int cells, which were functionally suppressive in
T cell proliferation assays and exhibited phenotypic characteris-
tics of MDSCs.422 Cell Reports 13, 412–424, October 13, 2015 ª2015 The AuthorsMDSCs are a heterogeneous population comprising mono-
cytic and granulocytic cells that employ a broad variety of sup-
pressive mechanisms (Gabrilovich and Nagaraj, 2009). It is well
established that MDSCs accumulate in the BM, blood, spleen,
and tumor of tumor-bearing mice and cancer patients and sup-
press T cell function (Gabrilovich and Nagaraj, 2009; Serafini
et al., 2006). MDSCs are comprised of two subsets: cells with
granulocytic phenotype that are Gr1high and cells with monocytic
phenotype that are Gr1int (Gabrilovich and Nagaraj, 2009; Peran-
zoni et al., 2010; Serafini et al., 2006), with CD11b+Gr1int cells
being the most suppressive (Dolcetti et al., 2010). Our data
demonstrated expansion of only CD11b+Gr1int monocytic
MDSCs in the B16-IDO tumors and showed that CD11b+Gr1int
population, but not CD11b+Gr1high cells, suppressed T cell func-
tion in vitro. Interestingly, CD11b+Gr1int cells derived from B16-
WT tumors were not suppressive, which was in concert with
previous findings from our group (Lesokhin et al., 2012). These
findings indicate that IDO expression by the tumor not only led
to expansion of the CD11b+Gr1int population but also conferred
suppressive properties upon these cells.
Previous studies have revealed a variety of mechanisms un-
derlying suppression of T cells by MDSCs, including Arg1-medi-
ated local depletion of nutrients (i.e., arginine and cysteine)
required for adequate T cell activation and expression of iNOS,
which leads to NO production (Gabrilovich and Nagaraj, 2009).
We found that CD11b+Gr1int cells within the B16-IDO tumors dis-
played higher levels of the suppressive enzymes Arg1 and NO
than CD11b+Gr1high cells, which could explain their distinct sup-
pressive capacity. Accordingly, immune suppressive activity of
CD11b+Gr1int MDSCs from B16-IDO tumors was partially
blocked by inhibition of Arg1 and iNOS. While phenotypically
CD11b+Gr1int MDSCs isolated from the B16-IDO tumors were
very similar to the CD11b+Gr1int cells from B16-WT tumors,
only the B16-IDO MDSCs were suppressive. Additional pheno-
typic markers have been previously linked to MDSC function,
including IL-4Ra, PD-L1, and TGF-b (Gabrilovich et al., 2012).
To this end, CD11b+Gr1int MDSCs fromB16-IDO tumors showed
upregulation of all of these factors (i.e., Arg1, NO, IL-4Ra, PD-L1,
and TGF-b) compared to CD11b+Gr1int cells from B16-WT
tumors.
The findings above were not only restricted to the B16-IDO
model but also noted in established 4T1 breast tumors naturally
expressing high levels of IDO. Importantly, we saw a similar as-
sociation in melanoma patients, where tumor expression of IDO
was strongly correlated with increased tumor-infiltrating
MDSCs. Finally, the recruitment and activation of MDSCs to
the B16-IDO tumors could be partially reversed by pharmaco-
logical inhibition of IDO. These studies thus establish an
important link between IDO expression and MDSC recruitment
to tumors and suggest a new pathway of IDO-mediated immu-
nosuppression. These findings are in concert with previous
studies demonstrating that genetic IDO deficiency results in
impaired activity of MDSCs (Smith et al., 2012).
Our results further revealed that the CD11b+G1int subpopula-
tion in mice with IDO+ tumors increased in numbers not just
within the tumor but in the spleen as well. Interestingly, the
CD11b+G1int enriched from spleens of B16-IDO tumor-bearing
mice did not show suppressive activity in vitro and displayed
low levels of both Arg1 and iNOS. Thus, in our model, the full
spectrum of MDSC suppressive functions might be acquired
not in the spleen but upon recruitment to the tumor. In support
of this, we found that functional CD11b+G1int MDSCs accumu-
lated in distant non-IDO-expressing B16 tumors in a bilateral
flank tumormodel bearing B16-IDO on one flank and B16-WT tu-
mors on the contralateral flank, and this was associated with
increased tumor growth of the B16-WT tumors. These findings
are in line with prior studies demonstrating that MDSCs actively
migrate to the site of the tumor, where they upregulate the
expression of Arg1 and iNOS, and downregulate the production
of ROS (Kusmartsev et al., 2004).
The mechanisms by which MDSC functions are activated
within the tumor microenvironment remain unclear. We
observed upregulation of inflammatory cytokines and growth
factors in the B16-IDO tumors, suggesting that the observed
recruitment and activation of MDSCs may be a part of an adap-
tive immune response. Indeed, we found that CD11b+Gr1+ cells
were not recruited, expanded or activated by the B16-IDO tu-
mors grown in Rag/ mice. T cells have previously been
demonstrated to play an important role in activation of MDSCs
in cancer (Gabrilovich and Nagaraj, 2009). Notably, we
observed an increase in the frequency of tumor-infiltrating high-
ly suppressive CD4+Foxp3+ Tregs in the B16-IDO tumors. Prior
studies have shown that IDO can induce and activate
CD4+Foxp3+ Tregs (Munn, 2012). These findings are suggestive
of a link between IDO, Tregs, and MDSCs, and indeed, systemic
depletion of Tregs in B16-IDO tumor-bearing mice significantly
reduced the number of tumor-infiltrating CD11b+Gr1int cells
and prevented migration of CD11b+Gr1int cells to IDO-express-
ing tumors in vitro. Furthermore, we found that the migration of
CD11b+Gr1int splenocytes to B16-IDO tumors harvested from
Rag/ mice was completely restored by addition of Tregs.
Finally, CD11b+Gr1int cells isolated form Treg-depleted mice
were functionally impaired in their ability to suppress T cells.
Thus, in addition to their direct T cell suppressive effects,
IDO-induced Tregs may also play an essential role in the recruit-
ment and activation of suppressive MDSCs. In support of these
findings, several studies have demonstrated a correlation be-
tween MDCSs and Tregs in a variety of cancers, including met-
astatic prostate cancer, glioblastoma, and renal cell carcinoma
(Gabrilovich et al., 2012), thus linking the two immune suppres-
sive cells subsets in cancer patients.
In summary, our findings indicate that IDO expression by the
tumors plays a key role in establishment of both local and sys-
temic immunosuppression, which is mediated by expansion,
recruitment, and activation of MDSCs in a Treg-dependent
manner. The aberrant expression of IDO has been identified
as a critical tipping point in progression of many different
cancers (Munn, 2012) and a logical focus for targeted therapy
(Liu et al., 2010). MDSCs have been shown to promote tumor
growth, survival, and treatment resistance in melanoma and
other cancers (Gabrilovich and Nagaraj, 2009). Understanding
the regulation of MDSC recruitment and function by IDO pro-
vides important insights into the link between IDO signaling
and development of the immunosuppressive tumor microenvi-
ronment and opens new opportunities for therapeutic
intervention.CEXPERIMENTAL PROCEDURES
Tumor Challenge and Treatment Experiments
All mouse procedures and experiments for this study were approved by the
Memorial Sloan Kettering Cancer Center Institutional Animal Care and Use
Committee. Details on mice and cell lines are provided in Supplemental
Experimental Procedures. On day 0 of the experiments, tumor cells were in-
jected intradermally (i.d.) in the flank. Treatments were given as single
agents or in combinations as described in Supplemental Experimental
Procedures.
Isolation of Tumor-Infiltrating Cells and Lymphoid Tissue Cells
Single-cell suspensions from mouse tissue were generated and stained with
indicated antibodies for immediate analysis and/or flow sorting as described
in Supplemental Experimental Procedures.
T Cell Suppression Assay
CD8+ cells were purified from single cell suspensions from spleens of naive
mice using anti-CD8 (Ly-2) microbeads (Miltenyi Biotech) according to manu-
facturer’s protocol and labeled with appropriate CellTrace Reagent. The
labeled CD8+ T cells were then plated onto round bottom 96-well plates
coated with 1 mg/ml anti-CD3 (clone 1454-2C11) and 5 mg/ml anti-CD28 (clone
37N). Purified suppressor cells (i.e., MDSCs or Foxp3+ Tregs) were added in
indicated ratios and plates were incubated at 37C. Percent CD8+ T cell pro-
liferation was measured by assessing dilution of the CellTrace Dye by flow
cytometry after 48–72 hr of culture (LSRII flow cytometer, BD Biosciences).
Controls were wells without suppressor cells (Stim+) and wells without sup-
pressor cells and anti-CD3/CD28 antibody (Stim). Details and specific con-
ditions are provided in Supplemental Experimental Procedures.
Cell Migration
Dissociated tumor cells were placed in the bottom chamber of a 24-well cell
culture plate. Purified MDSC splenocytes were labeled with 1 mM CellTrace
Far Red DDAO-SE (Thermo Fisher Scientific) and placed in the upper chamber
(3-mm cell culture inserts with polyethylene terephthalate membranes,
BD Falcon). MDSCs were allowed to migrate to the bottom well for 24 hr.
Migrated and labeled cells were then analyzed by flow cytometry on a LSRII
Flow Cytometer (BD Bioscience) and quantified using Count Bright Absolute
Counting Beads (Invitrogen). Percentage migration was calculated as (number
of migrated cells)3 100/(total cells added per well). IL-6, IL-10, MCP-1, IFN-g,
TNF, and IL-12p70 recombinant proteins (500 pg/ml, BDBioscience) (+) orme-
dia alone () were used for control chambers. Details and specific conditions
are provided in Supplemental Experimental Procedures.
In Vitro Differentiation of MDSCs
Purified MDSC splenocytes were labeled with CellTrace Far Red DDAO-SE
(Thermo Fisher Scientific) and cultured in complete RPMI media with or
without dissociated tumor cells at indicated numbers. Two days later, cells
were collected and DDAO-SE-labeled MDSCs were isolated by flow
(FACSAria II Cell Sorter, BD Biosciences). Dead cells were excluded using
DAPI (Invitrogen). The flow-sorted MDSCs were subsequently tested in
T cell suppression assays as described above.
Cytokine Measurements
Cytokine levels in homogenized tumors were measured using Luminex Mouse
Cytokine Magnetic 20-Plex Panel (Invitrogen) according to the manufacturer’s
instructions and as described in Supplemental Experimental Procedures.
In Vivo BrdU Staining
Tumor-bearing mice were injected with 2 mg BrdU intraperitoneally (i.p.). After
1 hr, micewere sacrificed and BM, blood, spleen, and tumor suspensionswere
prepared. BrdU incorporation inMDSCswas analyzed using the BDFITCBrdU
Flow Kit (BD Bioscience) according to the manufacturer’s instructions.
Arg1, NO, and ROS Activity
FACS-sorted MDSCs were washed and analyzed for Arg1, NO, and ROS pro-
duction as described in Supplemental Experimental Procedures.ell Reports 13, 412–424, October 13, 2015 ª2015 The Authors 423
TaqMan Gene Expression Analysis
Total RNA extraction and real-time analysis were performed as described in
Supplemental Experimental Procedures.
Isolation of Pmel Lymphocytes and Adoptive Transfer
Adoptive transfer of in vitro activated pmel cells was performed in mice 5 days
after tumor challenge as described in Supplemental Experimental Procedures.
Treg Depletion in Mice
Foxp3DTR mice were injected i.p. on 5 consecutive days with DT (250 ng/
mouse, Sigma-Aldrich). DT treatment was initiated 8–9 days after tumor inoc-
ulation when tumors exhibited a volume of 100 mm3.
Patient Material and Analysis
Patient samples were collected on a tissue-collection protocol approved by
the institutional review board. Details on processing and analysis are provided
in Supplemental Experimental Procedures.
Statistics
Statistics are described in Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2015.08.077.
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